X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with Biocon Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs BIOCON LTD - Comparison Results

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA BIOCON LTD ELDER PHARMA/
BIOCON LTD
 
P/E (TTM) x -0.2 36.6 - View Chart
P/BV x 0.1 4.9 2.1% View Chart
Dividend Yield % 0.0 1.5 -  

Financials

 ELDER PHARMA   BIOCON LTD
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
BIOCON LTD
Mar-16
ELDER PHARMA/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs380496 76.7%   
Low Rs188397 47.4%   
Sales per share (Unadj.) Rs491.2174.3 281.9%  
Earnings per share (Unadj.) Rs-3.244.8 -7.1%  
Cash flow per share (Unadj.) Rs14.456.9 25.3%  
Dividends per share (Unadj.) Rs05.00 0.0%  
Dividend yield (eoy) %01.1 0.0%  
Book value per share (Unadj.) Rs376.5202.8 185.7%  
Shares outstanding (eoy) m20.54200.00 10.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.62.6 22.6%   
Avg P/E ratio x-89.310.0 -896.5%  
P/CF ratio (eoy) x19.77.8 251.5%  
Price / Book Value ratio x0.82.2 34.3%  
Dividend payout %011.2 0.0%   
Avg Mkt Cap Rs m5,83389,220 6.5%   
No. of employees `000NA4.4 0.0%   
Total wages/salary Rs m2,1796,363 34.2%   
Avg. sales/employee Rs ThNM7,894.5-  
Avg. wages/employee Rs ThNM1,441.2-  
Avg. net profit/employee Rs ThNM2,029.7-  
INCOME DATA
Net Sales Rs m10,08934,854 28.9%  
Other income Rs m257845 30.4%   
Total revenues Rs m10,34635,699 29.0%   
Gross profit Rs m-7928,200 -9.7%  
Depreciation Rs m3612,423 14.9%   
Interest Rs m2,756102 2,702.3%   
Profit before tax Rs m-3,6536,520 -56.0%   
Minority Interest Rs m0-744 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,7135,754 64.5%   
Tax Rs m1252,569 4.9%   
Profit after tax Rs m-658,961 -0.7%  
Gross profit margin %-7.823.5 -33.4%  
Effective tax rate %-3.439.4 -8.7%   
Net profit margin %-0.625.7 -2.5%  
BALANCE SHEET DATA
Current assets Rs m9,24039,932 23.1%   
Current liabilities Rs m9,99816,276 61.4%   
Net working cap to sales %-7.567.9 -11.1%  
Current ratio x0.92.5 37.7%  
Inventory Days Days4654 86.5%  
Debtors Days Days6086 69.6%  
Net fixed assets Rs m10,12439,101 25.9%   
Share capital Rs m2061,000 20.6%   
"Free" reserves Rs m5,58238,591 14.5%   
Net worth Rs m7,73440,556 19.1%   
Long term debt Rs m4,88920,724 23.6%   
Total assets Rs m22,88284,816 27.0%  
Interest coverage x-0.364.9 -0.5%   
Debt to equity ratio x0.60.5 123.7%  
Sales to assets ratio x0.40.4 107.3%   
Return on assets %11.810.7 110.1%  
Return on equity %-0.822.1 -3.8%  
Return on capital %22.319.0 117.5%  
Exports to sales %3.030.7 9.9%   
Imports to sales %0.420.4 2.1%   
Exports (fob) Rs m30710,717 2.9%   
Imports (cif) Rs m437,105 0.6%   
Fx inflow Rs m30711,789 2.6%   
Fx outflow Rs m1258,393 1.5%   
Net fx Rs m1813,396 5.3%   
CASH FLOW
From Operations Rs m11,7545,264 223.3%  
From Investments Rs m-561-9,540 5.9%  
From Financial Activity Rs m-6,76210,867 -62.2%  
Net Cashflow Rs m4,4326,591 67.2%  

Share Holding

Indian Promoters % 39.6 40.4 98.0%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 7.5 8.4 89.3%  
FIIs % 16.8 10.7 157.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 19.9 181.4%  
Shareholders   16,479 109,995 15.0%  
Pledged promoter(s) holding % 77.6 0.0 193,900.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   PFIZER  GSK PHARMA  PANACEA BIOTECH  WYETH LTD  ABBOTT INDIA  

Compare ELDER PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Biocon: High Other Income And Licensing Income Drive Growth (Quarterly Results Update - Detailed)

Nov 7, 2016

Biocon has announced its 2QFY17. The company has reported 19.8% YoY growth in net sales and profits of Rs 1.5 bn for the quarter. Here is our analysis of the results.

Biocon: Lower R&D Expenses Help Margin Expansion (Quarterly Results Update - Detailed)

Sep 19, 2016

Biocon has announced its 1QFY17. The company has reported 21.1% YoY growth in total income and 34.6% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA - FULFORD INDIA COMPARISON

COMPARE ELDER PHARMA WITH

MARKET STATS